Cardiovascular Disease

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations compared with simvastatin alone, in women (27.9% vs 18.7%, p<0.001) and men (36.7% vs 18.5%, p<0.001), t

Effect: adverse; Women: 27.9% vs 18.7%; Men: 36.7% vs 18.5%

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD

A normal ankle-brachial index (0.9-1.3) performed poorly as a negative risk marker, providing minimal post-test risk change, despite being the most prevalent negative result (93% of participants).

Effect: null; DLR >0.80 for CVD